

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADO
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CaPlus and USPTAFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CaPlus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:01:11 ON 02 AUG 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:01:23 ON 02 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 AUG 2005 HIGHEST RN 857935-17-2

DICTIONARY FILE UPDATES: 1 AUG 2005 HIGHEST RN 857935-17-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s glycyrretic acid/cn

L1 0 GLYCYRRETINIC ACID/CN

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.03

5.24

FILE 'CAPLUS' ENTERED AT 15:01:55 ON 02 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Aug 2005 VOL 143 ISS 6
FILE LAST UPDATED: 1 Aug 2005 (20050801/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s glycyrrhetic acid
7 GLYCYRRHETINIC
4011602 ACID
1485594 ACIDS
4492140 ACID

(ACID OR ACIDS)
L2 7 GLYCYRRHETINIC ACID
(GLYCYRRHETINIC(W)ACID)

=> d scan

L2 7 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN
IC ICM C07C062-38
ICS C07C069-013; C07D313-06; C12P015-00
ICA A61K031-19; A61K031-365
ICI C12P015-00, C12R001-14
CC 16-2 (Fermentation and Bioindustrial Chemistry)
TI Manufacture of glycyrrhetic acid derivatives
ST glycyrrhetinate manuf microorganism; Chainia glycyrrhetinate fermn
IT Chainia antibiotica
(glycyrrhetic acid derivs. manufacture by)
IT Fermentation
(glycyrrhetic acid derivs., by Chainia antibiotica)
IT Inflammation inhibitors and Antiarthritics
(glycyrrhetic acid derivs., manufacture of, by Chainia antibiotica)
IT Allergy
Ulcer
(inhibitors, glycyrrhetic acid derivs., manufacture of, by Chainia antibiotica)
IT 471-53-4DP, derivs. 102292-08-0P 103488-78-4P 103498-64-2P
103498-65-3P 103515-15-7P 103562-30-7P 103880-69-9P 104901-14-6P
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP
(Preparation)
(manufacture of, with Chainia antibiotica)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 7 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN
IC C07C
INCL 260468500
CC 30-30 (Terpenoids)
Section cross-reference(s): 1
TI 18 β -Glycyrrhetic acid amides
ST antiulcer **glycyrrhetic acid** amide

IT Ulcer
(inhibitors, glycyrrhetic acid amides)

IT 471-53-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of amino acid derivs.)

IT 5680-80-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, by glycyrrhetic acid)

IT 3417-91-2 7524-52-9 13433-00-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, by oleanenoyl chloride)

IT 142-84-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, by Me carbobenzyloxyglutamate)

IT 4652-65-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)

IT 30151-31-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with amino acids)

IT 6277-14-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with thionyl chloride)

IT 2491-18-1P 7524-50-7P 18684-16-7P 39256-89-8P 51297-29-1P
51297-33-7P 51298-45-4P 51298-46-5P 51298-48-7P 51298-49-8P
51298-50-1P 51298-51-2P 51298-53-4P 51298-54-5P 51298-55-6P
51376-11-5P 55874-07-2P 55874-08-3P 55874-09-4P 55874-10-7P
55874-11-8P 55903-88-3P 55903-89-4P 55914-48-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 4070-43-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with benzyl chloroformate)

IT 501-53-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with ethyl aspartate)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 7 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN

CC 2-1 (Mammalian Hormones)

TI Mass spectrometry in the diagnosis of steroid-related disorders and in
hypertension research

ST mass spectrometry steroid related disorder diagnosis;
mineralocorticosteroid metab disorder diagnosis mass spectrometry;
licorice metabolite mass spectrometry; **glycyrrhetic**
acid mass spectrometry; urine steroid HPLC electrospray mass
spectrometry; liq chromatog mass spectrometry steroid urine

IT Steroids, analysis
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in urine of human by microbore HPLC combined with
electrospray mass spectrometry)

IT Mass spectrometry
(in steroid-related disorder diagnosis and hypertension research)

IT Diagnosis
(of steroid-related disorders, mass spectrometry in)

IT Urine analysis
(steroids determination in, of human by microbore HPLC combined with
electrospray mass spectrometry)

IT Chromatography, column and liquid
(high-performance, combined with mass spectrometry, for steroid
determination)

in urine of human)
 IT Steroids, biological studies
 RL: BIOL (Biological study)
 (metabolic disorders, mass spectrometry in diagnosis of)
 IT Corticosteroids, biological studies
 RL: BIOL (Biological study)
 (mineralo-, metabolic disorders, mass spectrometry in diagnosis of)
 IT 471-53-4
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in urine of human by microbore HPLC combined with
 electrospray mass spectrometry)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 7 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN
 IC C07C; A61K
 CC 30-30 (Terpenoids)
 Section cross-reference(s): 63
 TI **Glycyrrhetic acid** derivatives
 ST glycyrrhetinylaminobenzamide; benzamide glycyrrhetinylamino;
 metoclopramide glycyrrhetinyl; digestive tract glycyrrhetinyl
 metoclopramide
 IT Digestive tract
 (disorders of, glycyrrhetinylmetoclopramides in treatment of)
 IT 5356-59-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (chlorination of)
 IT 58096-33-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrolysis of)
 IT 58096-34-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oxidation of)
 IT 58096-35-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, with metoclopramide)
 IT 58096-36-9P 58096-37-0P 58096-38-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT 364-62-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with glycyrrhetic acid derivs.)
 IT 30151-31-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with metoclopramide)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 7 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN
 CC 1-2 (Pharmacology)
 TI Effect of human serum albumin on transport of drugs through human
 erythrocyte membranes
 ST serum albumin drug transport erythrocyte membrane
 IT Erythrocyte
 Pharmacokinetics
 (serum albumin effect on drug transport through human erythrocyte
 membranes)
 IT Albumins, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (serum albumin effect on drug transport through human erythrocyte

membranes)

IT Aglycons
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (serum albumin effect on drug transport through human erythrocyte membranes)

IT Glycosides
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (serum albumin effect on drug transport through human erythrocyte membranes)

IT 50-78-2, Aspirin 62-23-7, p-Nitrobenzoic acid 65-85-0, Benzoic acid, biological studies 69-72-7, o-Hydroxybenzoic acid, biological studies 74-11-3, p-Chlorobenzoic acid 88-65-3, o-Bromobenzoic acid 90-01-7, Saligenin 99-04-7, m-Toluic acid 99-05-8 99-06-9, biological studies 99-94-5, p-Toluic acid 99-96-7, p-Hydroxybenzoic acid, biological studies 100-02-7, p-Nitrophenol, biological studies 118-90-1, o-Toluic acid 118-91-2, o-Chlorobenzoic acid 118-92-3, o-Aminobenzoic acid 121-92-6, m-Nitrobenzoic acid 123-31-9, Hydroquinone, biological studies 138-52-3, Salicin 150-13-0, p-Aminobenzoic acid 303-07-1, γ -Resorcylic acid 445-29-4, o-Fluorobenzoic acid 455-38-9, m-Fluorobenzoic acid 456-22-4, p-Fluorobenzoic acid 471-53-4, Glycyrrhetic acid 487-54-7, Salicylic acid 497-76-7, Arbutin 535-80-8 552-16-9, o-Nitrobenzoic acid 585-76-2, m-Bromobenzoic acid 586-76-5, p-Bromobenzoic acid 1405-86-3, Glycyrrhizin
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (serum albumin effect on drug transport through human erythrocyte membranes)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 7 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN
 CC 1-5 (Pharmacodynamics)
 TI Antiinflammatory effect of glycyrrhetic acid derivatives
 ST glycyrrhetic acid deriv inflammation inhibitor
 IT Inflammation inhibitors
 (glycyrrhetic acid derivs.)

IT 7421-40-1 10251-37-3 66067-20-7 66067-21-8 66067-22-9 66101-51-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inflammation inhibition by)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 7 ANSWERS CAPLUS COPYRIGHT 2005 ACS on STN
 CC 11H (Biological Chemistry: Pharmacology)
 TI **Glycyrrhetic acid**-a triterpene with antiestrogenic and antiinflammatory activity

IT Inflammation
 (-inhibiting substances, glycyrrhetic acid as)

IT Estrogenic hormones
 (liver response to)

IT Estrogenic hormones
 (uterus response to, glycyrrhetic acid effect on)

IT 471-53-4, Olean-12-en-30-oic acid, 3 β -hydroxy-11-oxo-
 (as estrogen antagonist and inflammation inhibitor)

IT 50-78-2, Acetylsalicylic acid
 (inflammation inhibition by)

ALL ANSWERS HAVE BEEN SCANNED

=> file reg
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.13	10.37

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:04:00 ON 02 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 AUG 2005 HIGHEST RN 857935-17-2
DICTIONARY FILE UPDATES: 1 AUG 2005 HIGHEST RN 857935-17-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.


Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s 471-53-4
L3 1 471-53-4
(471-53-4/RN)

=> d str cn

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3 β ,20 β)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Olean-12-en-30-oic acid, 3 β -hydroxy-11-oxo- (8CI)

CN Uralenic acid (7CI)

OTHER NAMES:

CN α -Glycyrrhetic acid

CN 18 β -Glycyrrhetic acid

CN 18 β -Glycyrrhetic acid

CN Arthrodont

CN Biosone

CN Enoxolone

CN Glycyrrhetic acid

CN Glycyrrhetin

CN Glycyrrhetic acid

CN GM 1658

CN NSC 35347

CN PO 12

CN STX 352

CN Subglycyrrhelinic acid

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.70

13.07

FILE 'CAPLUS' ENTERED AT 15:04:56 ON 02 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Aug 2005 VOL 143 ISS 6

FILE LAST UPDATED: 1 Aug 2005 (20050801/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 471-53-4/rn

1466 471-53-4

122 471-53-4D

L4 1397 471-53-4/RN

(471-53-4 (NOTL) 471-53-4D)

=> s cosmetic? and L4

71289 COSMETIC?

L5 223 COSMETIC? AND L4

=> s retinoid?

L6 13662 RETINOID?

=> s L6 and L5

L7 14 L6 AND L5

=> s phosphatidylcholine

36800 PHOSPHATIDYLCHOLINE

30436 PHOSPHATIDYLCHOLINES

L8 48154 PHOSPHATIDYLCHOLINE

(PHOSPHATIDYLCHOLINE OR PHOSPHATIDYLCHOLINES)

=> s L7 and L8

L9 1 L7 AND L8

=> d 1 ibib abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:31216 CAPLUS

DOCUMENT NUMBER: 136:90707

TITLE: Skin conditioning compositions containing compounds for mimicking the effect of retinoic acid on skin

INVENTOR(S): Granger, Stewart Paton; Scott, Ian Richard; Donovan, Robert Mark; Iobst-Teklits, Susanne; Licameli, Lisa

PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever NV; Hindustan Lever Limited

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002074	A2	20020110	WO 2001-EP7234	20010625
WO 2002002074	A3	20030612		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2412788	AA	20020110	CA 2001-2412788	20010625

AU 2001079687	A5	20020114	AU 2001-79687	20010625
EP 1333800	A2	20030813	EP 2001-957886	20010625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012142	A	20031007	BR 2001-12142	20010625
JP 2004501952	T2	20040122	JP 2002-506696	20010625
ZA 2002010288	A	20031219	ZA 2002-10288	20021219
US 2004043044	A1	20040304	US 2003-312659	20030811
PRIORITY APPLN. INFO.:			US 2000-215301P	P 20000630
			WO 2001-EP7234	W 20010625

AB A skin care product comprising about 0.001-10% of a **retinoid**, in combination with at least two **retinoid** boosters (0.0001-50%). **Retinoid** boosters are selected from fatty acid amides, carotenoids, flavonoids, non-cyclic fragrance compds., phospholipid analogs, ureas, **phosphatidylcholines**, phosphatidylethanolamines, sphingomyelins, fatty acids, linseed oil, elaidic acid, bifonazole, climbazole, clotrimazole, econazole, quercetin, coumarin, quinolines, isoquinolines, etc. A composition according to the invention is intended primarily as a product for topical application to human skin, especially as an agent for conditioning and smoothening the skin, and preventing or reducing the appearance of wrinkled or aged skin. In use, a small quantity of the composition is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device. For example, a synergistic inhibition of transglutaminase, as a marker of skin differentiation, was observed by retinol with various quaternary combinations of **retinoid** boosters, e.g., acetyl sphingosine, **phosphatidylcholine**, linoleic acid, and climbazole.

=> d L7 1-14 ibib abs

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:57110 CAPLUS
 DOCUMENT NUMBER: 142:120194
 TITLE: **Cosmetic** and topical preparations containing extracellular polysaccharide of *Alteromonas macleodii* for alleviation of skin irritation
 INVENTOR(S): Ichiji, Yasushi
 PATENT ASSIGNEE(S): Arista Lifescience Corporation, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2005015375	A2	20050120	JP 2003-181255	20030625
PRIORITY APPLN. INFO.:			JP 2003-181255	20030625

AB Title prepns., useful for aftershave lotion, etc., contain extracellular polysaccharide-containing fermentation exts. of *A. macleodii*, which live in 2500-3000 m-deep sea water. Thus, the exts. inhibited rise of ICAM-1 in human keratinocyte and enhanced collagen matrix formation in human fibroblast cells.

L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:893261 CAPLUS
 DOCUMENT NUMBER: 142:120155
 TITLE: Skin external application agent for whitening skin
 INVENTOR(S): Lee, Byeong Gon
 PATENT ASSIGNEE(S): Pacific Co., Ltd., S. Korea
 SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given

DOCUMENT TYPE: CODEN: KRXXA7
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: Korean
 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2001060882	A	20010707	KR 1999-63340	19991228
PRIORITY APPLN. INFO.:			KR 1999-63340	19991228

AB An external application for whitening the skin comprising **retinoid**, vitamin C, a paper mulberry extract or the like is provided, which has excellent skin whitening effect on preventing skin hyperpigmentation such as freckles, ephelides and sun burn. The external application for whitening the skin comprises 0.01 to 20% by weight of a skin whitening agent containing 0.001 to 5% by weight of **retinoid**, 0.001 to 5% by weight of vitamin C, 0.001 to 5% by weight of a paper mulberry extract, 0.001 to 5% by weight of glycyrrhetic acid and 0.01 to 10% by weight of coenzyme Q10 based the total weight of the composition

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:681394 CAPLUS
 DOCUMENT NUMBER: 141:195313
 TITLE: Chemical enhancer and method
 INVENTOR(S): Hansenne, Isabelle; Cornell, Marc; Fares, Hani; Foltis, Sidney P.
 PATENT ASSIGNEE(S): L'Oreal S.A., Fr.
 SOURCE: U.S. Pat. Appl. Publ., 8 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004162272	A1	20040819	US 2003-367700	20030219
WO 2004073745	A1	20040902	WO 2004-EP1169	20040206
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-367700 A 20030219
 OTHER SOURCE(S): MARPAT 141:195313

AB The present invention relates to compns. containing at least one salicylic acid derivative and at least one **cosmetic**, dermatol., pharmaceutical, etc. active agent, where the salicylic acid derivative increases, enhances, etc., the efficacy of the active agent, as well as to methods of making and using such compns. The invention further relates to a method for enhancing the efficacy of active agents with these salicylic acid derivs. For example, a cream was formulated containing hydroquinone 4, capryloylsalicylic acid 1, glycerin 23, propylene glycol 6, dimethicone 20, dimethicone-vinyldimethicone copolymer 5, preservatives q.s., sequestrants q.s., antioxidants q.s., and water balance to 100 %.

L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:698734 CAPLUS

DOCUMENT NUMBER: 137:315740

TITLE: Composition for external use showing improvement effect on skin wrinkle and inhibition effect on wrinkle-formation

INVENTOR(S): Cho, Yun Gi; Hwang, Jae Seong; Kim, Jun O.; Lee, Jin Seon; Oh, Ji Yeon; Park, Byeong Hwa; Park, Won Man

PATENT ASSIGNEE(S): Pacific Co., Ltd., S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2001001290	A	20010105	KR 1999-20416	19990603
PRIORITY APPLN. INFO.:			KR 1999-20416	19990603

AB A composition for external use containing **retinoids**, vegetable sterols, isoflavonoid, cytokinins and glycyrrhetic acid is provided, which improves skin wrinkle and shows good inhibition effect on wrinkle-formation. A process for the preparation of antiwrinkle essence comprises: (1) mixing distilled water, glycerin, hyaluronic acid, β -glucan, and Carbomer at 70°; (2) adding retinol 0.00001-30 %, β -sitosterol 0.00001-30 %, genistein 0.00001-30 %, kinetin 0.00001-30 %, glycyrrhetic acid 0.00001-30 %, liquid paraffin, squalane, stearyl glucoside, sorbitan sesquioleate, cetearyl alc., preservatives, and perfumes to the above solution, (3) emulsifying and increasing viscosity by adding triethanolamine; and (4) eliminating bubbles and cooling to room temperature to get the objective essence.

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:521446 CAPLUS

DOCUMENT NUMBER: 137:83429

TITLE: Skin care product containing a **retinoid** and a **retinoid** booster system in a dual compartment package

INVENTOR(S): Granger, Stewart Paton; Pillai, Sreekumar; Scott, Ian Richard

PATENT ASSIGNEE(S): Unilever P.L.C., UK; Unilever N.V.; Hindustan Lever Limited

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053125	A2	20020711	WO 2001-EP14769	20011213
WO 2002053125	A3	20021003		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 2000-258460P P 20001228
 AB A stable skin care product contains a first composition comprising about 0.001-10% a **retinoid**, a second composition comprising 0.0001-50% at least 1 **retinoid** booster, a first compartment for storing the first composition, and a second compartment for storing the second composition, the first and second compartments being joined together. Thus, a combination of oleoyl hydroxyethylimidazoline and climbazole along with retinol inhibited the expression of transglutaminase.

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:521445 CAPLUS
 DOCUMENT NUMBER: 137:83428
 TITLE: Stable skin care compositions containing a **retinoid** and a **retinoid** booster system
 INVENTOR(S): Granger, Stewart Paton; Chandar, Prem; Scott, Ian Richard
 PATENT ASSIGNEE(S): Unilever P.L.C., UK; Unilever N.V.; Hindustan Lever Limited
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053124	A2	20020711	WO 2001-EP14491	20011206
WO 2002053124	A3	20030522		
WO 2002053124	B1	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003049286	A1	20030313	US 2001-8067	20011105
CA 2431540	AA	20020711	CA 2001-2431540	20011206
EP 1349536	A2	20031008	EP 2001-272638	20011206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004526690	T2	20040902	JP 2002-554075	20011206
ZA 2003004440	A	20040625	ZA 2003-4440	20030606
PRIORITY APPLN. INFO.: US 2000-258459P P 20001228 WO 2001-EP14491 W 20011206				
AB A stable skin care composition contains 0.0001-50% at least 1 retinoid booster, 0.001-10% a retinoid , and a cosmetically acceptable vehicle, wherein the stable skin care composition is contained in a package so that the composition is out of contact with oxygen. A synergistic inhibition of transglutaminase expression by a combination of oleoyl hydroxyethylimidazoline and climbazole with retinol was observed				

L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:521422 CAPLUS
 DOCUMENT NUMBER: 137:83423
 TITLE: Skin care product containing **retinoids**, **retinoid** booster and phytoestrogens in a dual

INVENTOR(S): compartment package
 Pillai, Sreekumar; Granger, Stewart Paton; Scott, Ian
 Richard; Pocalyko, David Joseph
 PATENT ASSIGNEE(S): Unilever P.L.C., UK; Unilever N.V.; Hindustan Lever
 Limited
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053108	A2	20020711	WO 2001-EP14486	20011206
WO 2002053108	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2002143059 A1 20021003 US 2001-3850 20011102 CA 2431539 AA 20020711 CA 2001-2431539 20011206 EP 1349538 A2 20031008 EP 2001-990538 20011206 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR ZA 2003003936 A 20040521 ZA 2003-3936 20011206 JP 2004522728 T2 20040729 JP 2002-554059 20011206 PRIORITY APPLN. INFO.: US 2000-258457P P 20001228 WO 2001-EP14486 W 20011206				

AB A stable skin care product contains a first composition comprising 0.001-10% a **retinoid**, a second composition comprising 0.0001-50% at least 1 **retinoid** booster and 0.001-10% a phytoestrogen. The products also contain a compartment for storing the first composition and a second compartment for storing the second composition, the first and second compartments being joined together. Synergy between genistein and daidzein and **retinoids** was tested. In both the studies genistein was delivered to the cells in a soluble form in DMSO/EtOH. Genistein (1 μ m) alone stimulated CRABP-2 significantly. Both genistein and daidzein stimulate **retinoid** activity in a synergistic manner. All the **retinoids** tested, except retinyl acetate showed synergy with genistein and daidzein. These data support our claim that the phytoestrogenic flavonoids genistein and daidzein, when supplied to cells in a soluble form, synergistically enhanced the activity of **retinoids**.

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:31216 CAPLUS
 DOCUMENT NUMBER: 136:90707
 TITLE: Skin conditioning compositions containing compounds for mimicking the effect of retinoic acid on skin
 INVENTOR(S): Granger, Stewart Paton; Scott, Ian Richard; Donovan, Robert Mark; Iobst-Teklits, Susanne; Licameli, Lisa
 PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever NV; Hindustan Lever Limited
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002074	A2	20020110	WO 2001-EP7234	20010625
WO 2002002074	A3	20030612		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412788	AA	20020110	CA 2001-2412788	20010625
AU 2001079687	A5	20020114	AU 2001-79687	20010625
EP 1333800	A2	20030813	EP 2001-957886	20010625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012142	A	20031007	BR 2001-12142	20010625
JP 2004501952	T2	20040122	JP 2002-506696	20010625
ZA 2002010288	A	20031219	ZA 2002-10288	20021219
US 2004043044	A1	20040304	US 2003-312659	20030811
PRIORITY APPLN. INFO.:				
			US 2000-215301P	P 20000630
			WO 2001-EP7234	W 20010625

AB A skin care product comprising about 0.001-10% of a **retinoid**, in combination with at least two **retinoid** boosters (0.0001-50%). **Retinoid** boosters are selected from fatty acid amides, carotenoids, flavonoids, non-cyclic fragrance compds., phospholipid analogs, ureas, phosphatidylcholines, phosphatidylethanolamines, sphingomyelins, fatty acids, linseed oil, elaidic acid, bifonazole, climbazole, clotrimazole, econazole, quercetin, coumarin, quinolines, isoquinolines, etc. A composition according to the invention is intended primarily as a product for topical application to human skin, especially as an agent for conditioning and smoothening the skin, and preventing or reducing the appearance of wrinkled or aged skin. In use, a small quantity of the composition is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device. For example, a synergistic inhibition of transglutaminase, as a marker of skin differentiation, was observed by retinol with various quaternary combinations of **retinoid** boosters, e.g., acetyl sphingosine, phosphatidylcholine, linoleic acid, and climbazole.

L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:703418 CAPLUS

DOCUMENT NUMBER: 135:247024

TITLE: **Cosmetics** containing Rhodiola extracts and other skin active agents

INVENTOR(S): Hoshino, Hiroshi; Hata, Tomonori; Sakata, Osamu; Okubo, Toshiaki

PATENT ASSIGNEE(S): Katsuako K. K., Japan; Kosei Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001261548	A2	20010926	JP 2000-80638	20000322
PRIORITY APPLN. INFO.:				
			JP 2000-80638	20000322

AB This invention relates to skin preps. comprising Rhodiola exts. and other active agents, such as skin-lightening agents, antioxidants, anti-inflammatories, and sunscreens. The compns. inhibit melanin production and show an excellent storage stability. A cream was formulated containing aqueous exts. of Rhodiola and placental hormones along with other conventional ingredients.

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:706945 CAPLUS

DOCUMENT NUMBER: 133:271409

TITLE: **Cosmetic** or dermatological compositions containing a substance for increasing the functionality and/or expression of CD44 membrane receptors of skin cells

INVENTOR(S): Dumas, Marc; Bonte, Frederic

PATENT ASSIGNEE(S): Parfums Christian Dior, Fr.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057836	A2	20001005	WO 2000-FR764	20000327
WO 2000057836	A3	20010517		
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2791260	A1	20000929	FR 1999-3840	19990326
FR 2791260	B1	20030606		
EP 1165035	A2	20020102	EP 2000-915224	20000327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002540126	T2	20021126	JP 2000-607587	20000327
US 2004043047	A1	20040304	US 2003-650965	20030829
PRIORITY APPLN. INFO.:			FR 1999-3840	A 19990326
			WO 2000-FR764	W 20000327
			US 2001-937507	B1 20010926

AB The invention relates to the uses in **cosmetics** or pharmaceuticals of at least one active agent for increasing the expression and/or functionality of CD44 membrane receptors of skin cells, enabling the fixation of hyaluronic acid and/or collagen, especially collagen I and/or collagen IV and/or fibronectin on the surface of said skin cells. Preferably, said active agents are alpha hydroxyl acids or alpha keto acids or salts and esters of said acids or manganese chloride. The inventive **cosmetic** or pharmaceutical compns. improve fixation of hyaluronic acid and/or collagen, especially collagen I or collagen IV and/or fibronectin on the surface of skin cells and improve hydration of the dermis and epidermis and prevent or treat skin-ageing phenomena and inflammatory phenomena. Efficacy of calcium gluconate on fixation of hyaluronic acid on cultured keratinocytes is shown. A moisturizer lotion contained calcium gluconate 0.1, Panax Ginseng extract 0.2, cAMP 0.05, caffeine 0.1, preservatives, perfumes and excipients q.s. 100 g.

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:783901 CAPLUS

DOCUMENT NUMBER: 132:26672

TITLE: Antiaging **cosmetic** composition containing a salt or a divalent metal complex

INVENTOR(S): Bonte, Frederic; Dumas, Marc; Heusele, Catherine; Le Blay, Jacques

PATENT ASSIGNEE(S): Guerlain S.A., Fr.; Le Blay, Jacques

SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962481	A1	19991209	WO 1999-FR1261	19990528
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2779059	A1	19991203	FR 1998-6822	19980529
FR 2779059	B1	20040910		
EP 1082098	A1	20010314	EP 1999-922237	19990528
R: CH, DE, ES, FR, GB, IT, LI				
JP 2002516838	T2	20020611	JP 2000-551738	19990528
US 6471972	B1	20021029	US 2000-701341	20001128
US 2003059484	A1	20030327	US 2002-244741	20020917
PRIORITY APPLN. INFO.:				
			FR 1998-6822	A 19980529
			US 1999-297679	A2 19990506
			FR 1996-13585	A 19961107
			WO 1999-FR1261	W 19990528
			US 2000-701341	A1 20001128

AB A **cosmetic** treatment method for fighting against skin aging effects is disclosed. The invention is characterized in that it consists in using at least one agent promoting the adherence of basal layer keratinocytes to the dermal-epidermal junction, particularly to said junction's collagen IV such as in particular a salt or a divalent metal complex, preferably magnesium aspartate or magnesium chloride optionally associated with an agent stimulating collagen IV synthesis and/or an agent stimulating collagen VII synthesis. The invention is useful for preparing **cosmetic** compns. with anti-wrinkle activity. Efficacy of 1 mM magnesium chloride and 0.25 mM magnesium aspartate in promotion of adherence of human keratinocytes to the collagen type IV is shown. An antiwrinkle cream contained magnesium L-aspartate 0.3, Potentilla erecta 0.01, sodium hyaluronate 0.06, glycerol 5.15, Centella asiatica 0.1, vitamin A palmitate 0.1, vitamin E acetate 0.5, Perilla dry extract 0.5, excipients, fragrances, and preservatives q.s. 100 g.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:549132 CAPLUS

DOCUMENT NUMBER: 131:174847

TITLE: **Cosmetic** composition comprising trace elements derived from mineral waters and chelated by plant protein hydrolysates

INVENTOR(S): Fort Lacoste, Lydie; Peyrot, Nicole; Navarro, Roger; Tournay, Alain

PATENT ASSIGNEE(S): Pierre Fabre Dermo-Cosmetique, Fr.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942082	A1	19990826	WO 1999-FR389	19990222
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				

PT, SE
 FR 2775185 A1 19990827 FR 1998-2130 19980223
 FR 2775185 B1 20010907
 EP 1056440 A1 20001206 EP 1999-904922 19990222
 EP 1056440 B1 20040915
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 AT 275931 E 20041015 AT 1999-904922 19990222
 PRIORITY APPLN. INFO.: FR 1998-2130 A 19980223
 WO 1999-FR389 W 19990222

AB A **cosmetic** composition for enhancing the condition and appearance of the skin and skin appendages, for stimulating cell regeneration and prevent skin ageing is disclosed. Said composition comprises as active principle minor elements derived from mineral waters and plant protein hydrolyzates which chelate said minor elements. The activity of trace element on the proliferation of fibroblasts and inhibition of free radicals was studied. An emulsion contained mineral oil 5, ethoxylated hydrogenated castor oil 5, triethanolamine 1.5, dimethicone 1, Carbomer 1, fragrances 0.2, trance elements 0.001-20 and mineral water q.s. 100%.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:222782 CAPLUS
 DOCUMENT NUMBER: 130:257188
 TITLE: Use of an excitatory amino acids inhibitors in **cosmetic** or dermatological compositions for sensitive skin
 INVENTOR(S): Breton, Lionel; Nonotte, Isabelle
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 904777	A1	19990331	EP 1998-402327	19980922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2768624	A1	19990326	FR 1997-11959	19970925
FR 2768624	B1	19991112		
CA 2245206	AA	19990325	CA 1998-2245206	19980924
JP 11158027	A2	19990615	JP 1998-270311	19980924
JP 2002193834	A2	20020710	JP 2001-328339	19980924
US 6616933	B1	20030909	US 1998-160151	19980925
US 2003202994	A1	20031030	US 2003-401685	20030331
PRIORITY APPLN. INFO.:			FR 1997-11959	A 19970925
			JP 1998-270311	A3 19980924
			US 1998-160151	A1 19980925

AB Excitatory amino acids inhibitor are used in **cosmetic** or dermatol. compns. for the treatment of skin irritations and erythema. A lotion for removing make-ups contained aniracetam 0.0001, antioxidants 0.05, isopropanol 40.00, preservative 0.30, and water q.s. 100%.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:157347 CAPLUS
 DOCUMENT NUMBER: 128:221456
 TITLE: Skin care compositions containing a polycyclic triterpene carboxylic acid and a **retinoid**

INVENTOR(S): Granger, Stewart Paton; Scott, Ian Richard
 PATENT ASSIGNEE(S): Chesebrough-Pond's USA Co., USA
 SOURCE: U.S., 7 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5723139	A	19980303	US 1996-721878	19960927
CA 2266615	AA	19980402	CA 1997-2266615	19970918
WO 9813019	A1	19980402	WO 1997-EP5139	19970918
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9747755	A1	19980417	AU 1997-47755	19970918
AU 714984	B2	20000113		
BR 9712135	A	19990831	BR 1997-12135	19970918
CN 1237897	A	19991208	CN 1997-199920	19970918
EP 975319	A1	20000202	EP 1997-910309	19970918
EP 975319	B1	20030402		
R: CH, DE, ES, FR, GB, LI				
JP 2000503030	T2	20000314	JP 1998-515236	19970918
RU 2175546	C2	20011110	RU 1999-108678	19970918
CZ 289876	B6	20020417	CZ 1999-1088	19970918
IN 189578	A	20030329	IN 1997-BO550	19970924
ZA 9708658	A	19990326	ZA 1997-8658	19970926
TW 541182	B	20030711	TW 1997-86118988	19971216
KR 2000048698	A	20000725	KR 1999-702653	19990327
PRIORITY APPLN. INFO.:			US 1996-721878	A 19960927
			WO 1997-EP5139	W 19970918

OTHER SOURCE(S): MARPAT 128:221456

AB A polycyclic triterpene carboxylic acid in combination with either retinol or retinyl ester resulted in a synergistic inhibition of keratinocyte differentiation. The effects of polycyclic triterpene carboxylic acids in combination with retinol or retinyl ester were analogous to the treatment with retinoic acid. Combination of 2.5×10^{-9} M retinol and 10^{-6} M glycyrrhizic acid repressed keratinocyte TG1 to 45% of control levels, therefore acted synergistically to repress keratinocyte differentiation in an analogous manner to the effect of retinoic acid. An water in oil emulsion contained retinol 0.5, fully hydrogenated coconut oil 3.9, ursolic acid 5, Brij 92 5, bentone 38 0.5, MgSO4 7H2O 0.3, butylated hydroxy toluene 0.01, perfume and water q.s. 100%.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hist

(FILE 'HOME' ENTERED AT 15:01:11 ON 02 AUG 2005)

FILE 'REGISTRY' ENTERED AT 15:01:23 ON 02 AUG 2005

L1 0 S GLYCYRRETNIC ACID/CN

FILE 'CAPLUS' ENTERED AT 15:01:55 ON 02 AUG 2005

L2 7 S GLYCYRRETNIC ACID

sphingomyelins, fatty acids, linseed oil, elaidic acid, bifonazole, climbazole, clotrimazole, econazole, quercetin, coumarin, quinolines, isoquinolines, etc. A composition according to the invention is intended primarily as a product for topical application to human skin, especially as an agent for conditioning and smoothening the skin, and preventing or reducing the appearance of wrinkled or aged skin. In use, a small quantity of the composition is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device. For example, a synergistic inhibition of transglutaminase, as a marker of skin differentiation, was observed by retinol with various quaternary combinations of **retinoid** boosters, e.g., acetyl sphingosine, **phosphatidylcholine**, linoleic acid, and climbazole.